Last reviewed · How we verify
3-mixtatin
At a glance
| Generic name | 3-mixtatin |
|---|---|
| Also known as | 3mixtatin |
| Sponsor | Mahmoud M Saadoon |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of 3Mixtatin Pulpotomy and Metapex Pulpectomy in Primary Molars With Irreversible Pulpitis (PHASE1)
- 3Mixtatin and MTA Vital Pulpotomy in Primary Molars (PHASE1)
- Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3-mixtatin CI brief — competitive landscape report
- 3-mixtatin updates RSS · CI watch RSS
- Mahmoud M Saadoon portfolio CI